2025-10-24 - Analysis Report
Okay, here's a comprehensive analysis of TG Therapeutics Inc. (TGTX) based on the provided data, formatted in English with a focus on key metrics and actionable insights.

## TG Therapeutics Inc. (TGTX) Analysis

**Company Overview:** TG Therapeutics is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 85.47%
*   **VOO Cumulative Return:** 99.09%
*   **Difference:** -14.0
*   **Relative Deviation:** 21.4 (This indicates that TGTX's underperformance relative to VOO is currently at the 21.4th percentile of its historical range, suggesting it's closer to its worst relative performance than its best)

**Analysis:** TGTX has underperformed the S&P 500 over the observed period. The relative deviation suggests that this underperformance is significant compared to its historical performance range.

**Table of Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha  | Beta  | Cap (B) |
| :----------- | :------ | :----- | :----- | :---- | :------ |
| 2015-2017  | -4.0%   | 75.5%  | -32.0% | 0.0   | 1.2     |
| 2016-2018  | -18.0%  | 73.7%  | -34.0% | -0.0  | 0.6     |
| 2017-2019  | 74.0%   | 74.2%  | 52.0%  | 0.0   | 1.7     |
| 2018-2020  | 320.0%  | 74.2%  | 296.0% | 0.1   | 7.8     |
| 2019-2021  | 126.0%  | 74.2%  | 79.0%  | 0.3   | 2.9     |
| 2020-2022  | -73.0%  | 77.8%  | -72.0% | -0.1  | 1.8     |
| 2021-2023  | -289.0% | 77.8%  | -291.0% | -0.8  | 2.6     |
| 2022-2024  | 56.0%   | 77.8%  | 36.0%  | -0.6  | 4.5     |
| 2023-2025  | 85.0%   | 80.4%  | 21.0%  | 0.8   | 5.3     |

**Analysis:**

*   **CAGR:** Highly volatile, ranging from significant losses (-289%) to substantial gains (320%).  Recent years show positive growth.
*   **MDD:** Consistently high Maximum Drawdown (around 74-80%), indicating high risk.
*   **Alpha:** Varies significantly, reflecting periods of both substantial outperformance and underperformance relative to the market.
*   **Beta:** Generally low, suggesting relatively low systematic risk, but fluctuating values indicate changing market sensitivity.
*   **Cap (B):** The market capitalization has fluctuated over the years.

### 2. Recent Stock Price Movement

*   **Current Price:** 35.22
*   **Last Market Data:** Price: 33.49, Previous Close: 34.59, Change: -3.18 (-9.28%)
*   **5-day Moving Average:** 34.99
*   **20-day Moving Average:** 35.40
*   **60-day Moving Average:** 32.20

**Analysis:** The stock price is below both the 5-day and 20-day moving averages but above the 60-day moving average, indicating a potential short-term downtrend but a longer-term uptrend. The significant negative change in the last market indicates substantial selling pressure and a potential negative catalyst.

### 3. Market Risk Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended) - but recent Hybrid Signal suggests caution
*   **RSI:** 37.99 (Approaching oversold territory)
*   **PPO:** -0.59 (Below zero, suggesting a downtrend)
*   **Hybrid Signal:** Cash 80% - Sell 80% of holdings (Risky - MRI:0.50).  This is a strong signal to reduce exposure.
*   **Recent (20-day) Relative Deviation Change:** +0.4 (Short-term increase)
*   **Expected Return:** -105.3% (Significant underperformance expected vs. S&P 500 over a long-term investment horizon)

**Analysis:** The MRI suggests a high investment recommendation, but the Hybrid Signal strongly contradicts this, advising significant risk reduction and a large cash position.  The RSI is approaching oversold, which could signal a potential bounce, but the negative PPO and expected return are concerning. The recent relative deviation increase offers a slight positive note, but the overall picture is bearish. The Last-market price drop is big enough to influence a negative outlook.

### 4. Recent News & Significant Events

*   **Positive:**
    *   Institutional investors are significant holders and benefitted from recent market cap gains.
    *   6-year data shows a high percentage of multiple sclerosis patients free from progression on Briumvi.
*   **Neutral:**
    *   Neuraxpharm's participation in ECTRIMS.

**Analysis:** The news is mixed. The Briumvi data is a significant positive, indicating the drug's efficacy. The institutional investor activity suggests confidence from some players.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 1.78)
*   **Target Price:** Average: $43.57, High: $60.00, Low: $11.00
*   **Recent Rating Changes:** Not specified in the provided information

**Analysis:** Analysts are generally positive on TGTX, with a consensus rating of "Buy" and a significant potential upside based on the average target price. However, the wide range between the high and low target prices ($11.00 - $60.00) indicates significant uncertainty among analysts.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue     |
| :---------- | :--- | :---------- |
| 2025-08-08 | 0.19 | $0.14B      |
| 2025-05-09 | 0.03 | $0.12B      |
| 2024-11-07 | 0.03 | $0.08B      |
| 2024-08-09 | 0.05 | $0.07B      |
| 2025-08-08 | 0.05 | $0.07B      |

**Analysis:** The most recent quarter (2025-08-08) shows a significant increase in both EPS and Revenue, indicating strong growth.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
| :--------- | :--------- | :-------------- |
| 2025-06-30 | \$0.14B   | 86.58%        |
| 2025-03-31 | \$0.12B   | 87.14%        |
| 2024-12-31 | \$0.11B   | 85.77%        |
| 2024-09-30 | \$0.08B   | 88.86%        |
| 2024-06-30 | \$0.07B   | 88.70%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE     |
| :--------- | :--------- | :------ |
| 2025-06-30 | \$0.28B   | 10.20% |
| 2025-03-31 | \$0.24B   | 2.13%  |
| 2024-12-31 | \$0.22B   | 10.49% |
| 2024-09-30 | \$0.19B   | 2.02%  |
| 2024-06-30 | \$0.18B   | 3.87%  |

**Analysis:**

*   **Revenue & Profitability:** Revenue has been steadily increasing, and profit margins are exceptionally high, indicating strong operational efficiency and pricing power.
*   **Capital & Profitability:** Equity has been increasing, and ROE has fluctuated, with the most recent quarter showing a strong return.

### 7. 종합적인 분석 (Overall Summary)

TGTX presents a mixed investment picture.

*   **Positives:** Strong recent earnings and revenue growth, very high profit margins, positive analyst consensus, promising clinical data for Briumvi.
*   **Negatives:**  Recent significant price drop, underperformance vs. S&P 500, high historical volatility (MDD), negative expected return, a Hybrid Signal recommending significant risk reduction (cash position), and conflicting MRI reading.

**Conclusion:** While TGTX has shown recent positive financial performance and promising clinical trial results, the significant price volatility, underperformance relative to the market, and conflicting signals from technical indicators warrant caution. The Hybrid Signal's recommendation to reduce exposure is particularly concerning.

**Recommendation:** Given the conflicting signals, a neutral to slightly bearish stance is warranted. Investors should closely monitor the stock's price action, news flow related to Briumvi, and any updates on the company's financial performance. Initiating or increasing a position at this time appears risky without further positive confirmation. The recent market volatility from the 'Last-market' data should not be ignored.
